A

Alphamab Oncology
9966

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
HK$9.28B
EV
HK$7.81B
Shares Outstanding
996.17M
Beta
0.37

Wall Street View

Analyst Rating
BUY
Analyst Target Price
HK$6.59
P/E 2025E
-
P/Revenue 2025E
18.30x

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Alphamab Oncology

gainify

A

Alphamab Oncology

9966

Alphamab Oncology, a clinical stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of oncology biologics. Its product pipeline includes KN046, a bispecific monoclonal antibody (BsAb) immune checkpoint inhibitor, ...

Sector

Healthcare

Industry

Biotechnology

CEO

Xu, Ting

Employees

420

IPO Date

2019-12-12

Headquarters

No. 175 Fangzhou Road, Suzhou Industrial Park, Suzhou, Jiangsu Province China

gainifypowered-by-sp
Socials
Send us an emailFollow us on XConnect with us on LinkedInFollow us on InstagramFollow us on ThreadsCheck us out on TrustpilotFollow us on YouTubeFind us on Google Maps

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2025 Gainify. All rights reserved.